tag:blogger.com,1999:blog-6097510160054715524.post3678838623463545609..comments2024-01-03T21:42:28.979-08:00Comments on DivGro: Recent Transfer: AbbVie Inc.FerdiShttp://www.blogger.com/profile/05008021146951839361noreply@blogger.comBlogger6125tag:blogger.com,1999:blog-6097510160054715524.post-84702509248661960432015-11-23T12:57:44.726-08:002015-11-23T12:57:44.726-08:00Thanks, BSR -- a Morningstar analyst is estimating...Thanks, BSR -- a Morningstar analyst is estimating a 20% decline in revenue for Humira by 2019 and gives ABBV a narrow moat assessment. On the other hand, he raised fair value to $65 from $58. With ABBV trading at $61 right now, that would represent a 7% discount.FerdiShttps://www.blogger.com/profile/05008021146951839361noreply@blogger.comtag:blogger.com,1999:blog-6097510160054715524.post-3429577794228189172015-11-23T12:44:11.836-08:002015-11-23T12:44:11.836-08:00Good buy although I heard about the Humira patent ...Good buy although I heard about the Humira patent expiration as well but you are on top of it. Good luck with ABBV!<br /><br />Cheers!<br /><br />BSR BeSmartRichhttp://www.besmartrich.comnoreply@blogger.comtag:blogger.com,1999:blog-6097510160054715524.post-35542100443359224512015-11-23T10:31:29.902-08:002015-11-23T10:31:29.902-08:00The patent expires toward the end of 2016 in the U...The patent expires toward the end of 2016 in the USA and in 2018 in Europe. From what I've read, the biologic composition of Humira would make generic completion difficult, since ABBV holds several hundred additional patents on how the drug is formulated and manufactured, which don't expire until 2022. Though revenue will be impacted from competition, there seems to be a barrier to entry. Several other drugs are in the pipeline, including Imbruvica, a blood cancer drug with strong clinical results. <br /><br />It would be interesting to see how ABBV navigates this environment!<br />FerdiShttps://www.blogger.com/profile/05008021146951839361noreply@blogger.comtag:blogger.com,1999:blog-6097510160054715524.post-562214902802774662015-11-23T08:16:09.296-08:002015-11-23T08:16:09.296-08:00ABBV's coming Humira patent expiration scares ...ABBV's coming Humira patent expiration scares me. The company gets the bulk of its revenue from Humira. The yield is nice though. Humira's the big unknown - how much will losing patent protection impact sales? If it's just a little, the stock is an absolute bargain. If it's a lot, then it's a value trap.Ben at Sure Dividendhttp://www.suredividend.comnoreply@blogger.comtag:blogger.com,1999:blog-6097510160054715524.post-45273148750422216222015-11-22T22:58:19.542-08:002015-11-22T22:58:19.542-08:00I'm a "latecomer" to ABBV, but I rea...I'm a "latecomer" to ABBV, but I really like the prospects. I think I'll also add to my position if the stock takes another drop! <br /><br />I'm actually keeping my Scottrade account. Earlier, the stocks in my Scottrade account were a mix of speculative and dividend paying stocks. Now I only have dividend paying stocks, so I figured I'd like to track them in the same way as my DivGro stocks (hosted at FolioInvesting). These "transfer" posts is my way of capturing the necessary details. FerdiShttps://www.blogger.com/profile/05008021146951839361noreply@blogger.comtag:blogger.com,1999:blog-6097510160054715524.post-23367829499184796712015-11-22T22:43:02.864-08:002015-11-22T22:43:02.864-08:00I do own shares of ABBV and plan to keep them for ...I do own shares of ABBV and plan to keep them for the foreseeable future. I have not added to that position in some time but if another major drop occurs like what happened a few weeks ago I'll jump in again. What brokerage are you moving to from Scottrade?DivHuthttp://divhut.comnoreply@blogger.com